Methoxetamine: Difference between revisions

>Gudetama
m Fixed formatting error.
>Blackhole
added important category
 
(6 intermediate revisions by 3 users not shown)
Line 22: Line 22:
MXE acts as a non-competitive [[NMDA receptor antagonist]] and [[serotonin]]-[[Reuptake Inhibitor|reuptake inhibitor]].<ref name="ACMDMXE2012" /> NMDA receptors allow for electrical signals to pass between neurons in the brain and spinal column; for the signals to pass, the receptor must be open. Dissociatives close the NMDA receptors by blocking them. This disconnection of neurons leads to loss of feeling, difficulty moving, and eventually an almost identical equivalent of the famous “[http://en.wikipedia.org/wiki/K-hole k-hole].” MXE was reported to be similar to [[Ketamine|ketamine]] <ref>{{cite journal | vauthors=((Kjellgren, A.)), ((Jonsson, K.)) | journal=Journal of Psychoactive Drugs | title=Methoxetamine (MXE) – A Phenomenological Study of Experiences Induced by a “Legal High” from the Internet | volume=45 | issue=3 | pages=276–286 | date=1 July 2013 | url=https://www.tandfonline.com/doi/full/10.1080/02791072.2013.803647 | issn=0279-1072 | doi=10.1080/02791072.2013.803647}}</ref>, despite being stronger and having a longer duration. <ref>{{cite journal | vauthors=((Coppola, M.)), ((Mondola, R.)) | journal=Medical Hypotheses | title=Methoxetamine: From drug of abuse to rapid-acting antidepressant | volume=79 | issue=4 | pages=504–507 | date= October 2012 | url=https://linkinghub.elsevier.com/retrieve/pii/S030698771200312X | issn=03069877 | doi=10.1016/j.mehy.2012.07.002}}</ref>
MXE acts as a non-competitive [[NMDA receptor antagonist]] and [[serotonin]]-[[Reuptake Inhibitor|reuptake inhibitor]].<ref name="ACMDMXE2012" /> NMDA receptors allow for electrical signals to pass between neurons in the brain and spinal column; for the signals to pass, the receptor must be open. Dissociatives close the NMDA receptors by blocking them. This disconnection of neurons leads to loss of feeling, difficulty moving, and eventually an almost identical equivalent of the famous “[http://en.wikipedia.org/wiki/K-hole k-hole].” MXE was reported to be similar to [[Ketamine|ketamine]] <ref>{{cite journal | vauthors=((Kjellgren, A.)), ((Jonsson, K.)) | journal=Journal of Psychoactive Drugs | title=Methoxetamine (MXE) – A Phenomenological Study of Experiences Induced by a “Legal High” from the Internet | volume=45 | issue=3 | pages=276–286 | date=1 July 2013 | url=https://www.tandfonline.com/doi/full/10.1080/02791072.2013.803647 | issn=0279-1072 | doi=10.1080/02791072.2013.803647}}</ref>, despite being stronger and having a longer duration. <ref>{{cite journal | vauthors=((Coppola, M.)), ((Mondola, R.)) | journal=Medical Hypotheses | title=Methoxetamine: From drug of abuse to rapid-acting antidepressant | volume=79 | issue=4 | pages=504–507 | date= October 2012 | url=https://linkinghub.elsevier.com/retrieve/pii/S030698771200312X | issn=03069877 | doi=10.1016/j.mehy.2012.07.002}}</ref>


Because of its structural similarity to [https://en.wikipedia.org/wiki/3-HO-PCP 3-HO-PCP], it was falsely believed to carry [[opioid]] properties.<ref>{{cite journal | vauthors=((Morris, H.)), ((Wallach, J.)) | journal=Drug Testing and Analysis | title=From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs: PCP to MXE | volume=6 | issue=7–8 | pages=614–632 | date= July 2014 | url=https://onlinelibrary.wiley.com/doi/10.1002/dta.1620 | issn=19427603 | doi=10.1002/dta.1620}}</ref> This claim cannot be supported by actual data, instead showing only insignificant affinity for the µ-opioid receptor by the substance itself, although in-vivo metabolites could yield different effects.<ref name="ACMDMXE2012" />
Because of its structural similarity to [https://en.wikipedia.org/wiki/3-HO-PCP 3-HO-PCP], it was falsely believed to carry [[opioid]] properties.<ref>{{cite journal | vauthors=((Morris, H.)), ((Wallach, J.)) | journal=Drug Testing and Analysis | title=From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs: PCP to MXE | volume=6 | issue=7–8 | pages=614–632 | date= July 2014 | url=https://onlinelibrary.wiley.com/doi/10.1002/dta.1620 | issn=19427603 | doi=10.1002/dta.1620}}</ref> This claim cannot be supported by actual data, instead showing only insignificant affinity for the µ-opioid receptor by the substance itself, although in-vivo metabolites could yield different effects.<ref name="ACMDMXE2012"/>


==Subjective effects==
==Subjective effects==
Line 194: Line 194:
*'''Turkey''': Methoxetamine is regulated under the Law on Control of Narcotics no. 2313.<ref name="JointReport" />
*'''Turkey''': Methoxetamine is regulated under the Law on Control of Narcotics no. 2313.<ref name="JointReport" />
*'''United Kingdom''': MXE is a Class B drug.{{citation needed}}
*'''United Kingdom''': MXE is a Class B drug.{{citation needed}}
*'''United States'''<nowiki>: MXE is now a schedule 1 controlled substance as of July 6th 2022 {{</nowiki>https://www.federalregister.gov/documents/2022/06/06/2022-11933/schedules-of-controlled-substances-placement-of-methoxetamine-mxe-in-schedule-i<nowiki>}}</nowiki>
*'''United States''': MXE is a schedule 1 controlled substance.<ref>https://www.federalregister.gov/documents/2022/06/06/2022-11933/schedules-of-controlled-substances-placement-of-methoxetamine-mxe-in-schedule-i</ref>


==See also==
==See also==
Line 223: Line 223:
<references />
<references />


[[Category:Psychoactive substance]]
[[Category:Arylcyclohexylamine]]
[[Category:Arylcyclohexylamine]]
[[Category:Dissociative]]
[[Category:Dissociative]]